What are your top takeaways in Breast Cancer from ASCO 2025?

My Top 3 takeaways in Breast Cancer from ASCO 2025

1. ASCENT-04: Sacituzumab Govitecan Plus Pembrolizumab as a New First-Line Standard for Metastatic PD-L1-Positive Triple Negative Breast Cancer (TNBC): The treatment landscape for metastatic TNBC continues to evolve rapidly. At ASCO 2025, presentation ...

I would say the top 3 presentations for breast cancer at ASCO 2025 were:

1. ASCENT-04: Impact: Sacituzumab and Pembrolizumab is a new first-line combination option for patients with untreated PD-L1+ metastatic TNBC. PFS and duration of response looked great; overall survival pending.
   
   
2. DESTINY-Breast 09:...

Here are my two cents:

1. SERENA‑6: evaluated a strategy of ctDNA‑guided early intervention, enrolling HR⁺/HER2⁻ patients on first‑line AI plus CDK4/6 therapy and monitoring for emergent ESR1 mutations. Upon detecting a mutation—prior to radiologic progression—patients were randomized to switch the AI...

The top 3 presentations, in my opinion, were:

1. SERENA 6 trial
2. DESTINY Breast 09
3. Overall survival improvement in INAVO 120 trial

Top three:

1. SERENA-6: demonstration that change of treatment based on molecular changes prior to clinical progression can substantially improve PFS in 1st line MBC.
   
   
2. DB-09: T-DxD likely the new SOC for 1st line HER2-positive MBC, though there will be debate on how long to give it.
   
   
3. ASCENT-04: SG/pembr...

My biggest takeaway from the high-profile breast cancer studies presented at ASCO this year is how good we have become at designing and rapidly conducting trials that could lead to regulatory approval, but leave it open if the results improve patient outcomes... The two cases in point are DESTINY Br...

1. ASCENT-04: data presented by Sara Tolaney showing 1st line data with sacituzumab plus pembrolizumab outperforming KY-355 will likely result in patients routinely getting this combination as SOC. The press release on ASCENT-03 also means it may do the same in those 1st line metastatic TNBC patients ...

1. INAVO120: INAVO120 survival advantage for use of PI3K targeting in PI3Km ER+ BC. Admittedly, the study did not allow crossover; thus, one cannot say that PI3K targeting is required in first-line treatment of high-risk metastatic patients. However, it does indicate that the responses seen with such ...